Key Insights from ASH 2025

In this episode of CancerCast, Dr. Manish Shah is joined by Drs. Gail Roboz and Rick Furman, two internationally renowned Weill Cornell leaders in advancing therapies for leukemia and lymphoma, to preview groundbreaking research from the 2025 American Society of Hematology (ASH) Annual Meeting. Drs. Roboz and Furman highlight some of the most impactful abstracts to be presented during the meeting, detailing how these key research developments are poised to impact patients and the hematology field at-large. Tune in to hear more about the cutting-edge science with expert insights into how these innovations are transforming cancer care.

The ASH annual meeting is the largest medical conference in the world dedicated to malignant and benign hematology, bringing together over 30,000 experts from around the world to share the latest research and advancements. Abstracts and studies discussed in this episode include PARADIGM, AML17, AML19, KOMET-007, CaDAnCe-101, CLL17, R-pola-glo, FLAIR, and more.

Gail Roboz, MD, Director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital.

Richard Furman, MD, Director of the Chronic Lymphocytic Leukemia (CLL) Research Center at Weill Cornell Medicine.

Host: Manish Shah, MD, Chief of Solid Tumor Service and Director of Gastrointestinal Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital.